Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
204 2 |
Ultima descărcare din IBN: 2023-08-31 16:39 |
Căutarea după subiecte similare conform CZU |
616.441-006.441-091.8 (1) |
Patologia sistemului limfatic, a organelor hemopoietice şi endocrine (189) |
SM ISO690:2012 BURSACOVSCHI, Daniela, CAZACU, Janna, CABAC-POGOREVICI, Irina, ROBU, Maria. The importance of comorbidity index and frailty prevalence in the evolution of large B-cell non-Hodgkin lymphoma. In: Revista de Ştiinţe ale Sănătăţii din Moldova, 2022, nr. 3 An.1(29), p. 165. ISSN 2345-1467. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Revista de Ştiinţe ale Sănătăţii din Moldova | ||||||
Numărul 3 An.1(29) / 2022 / ISSN 2345-1467 | ||||||
|
||||||
CZU: 616.441-006.441-091.8 | ||||||
Pag. 165-165 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Diffuse large B-cell lymphoma (DLBCL) is the global most common type of malignant lymphoma. Comorbidity and frailty are important independent predictors of mortality and treatment response. Objective of the study. This study investigated the prevalence of frailty in DLBCL patients and assessed its association to the comorbidity indexes. Material and Methods. Our descriptive study included a sample of 50 patients with DLBCL that initiated R-CHOP treatment regimen. We used Edmonton Frailty Scale (EFS) and the Charlson Comorbidity Index (CCI). A multiple linear regression model was applied to examine the association between CCI and EFS. Results. The mean age was 68.5 (±6.4) years, 32 (64%) were men and 18 (36%) were women. The mean CCI for all patients was 1.3; (CI 95%, 0.96-1.8). The mean EFS results for the sample was 2.1; (CI 95%, 1.4-2.6). The incidence of frailty (mild, moderate, and severe) was 32%, and apparently vulnerable was 68%. The models resulted in strong linear correlation in the estimation of the B-cell lymphoma therapeutic results, R² = 0.82, p = 0.0002. Conclusions. The prevalence of frailty was higher in older people. We have obtained a positive correlation between CCI and EFS. Further analysis is needed to appreciate the impact of these scales on survival rate and toxicity related rates |
||||||
Cuvinte-cheie non-Hodgkin’s lymphoma, cardiotoxicity, frailty, limfom non-Hodgkin, cardiotoxicitate, fragilitate |
||||||
|